COMPOSITION FOR INHIBITING HAIR GRAYING, AND USE THEREOF

Abstract

Provided is a composition for inhibiting hair graying, having an excellent effect of preventing the occurrence of gray hair, and a use thereof. A composition for inhibiting hair graying, of the presently claimed subject matter, activates the Wnt and β-catenin signaling pathway to promote melanin synthesis in hair, thereby having remarkably excellent hair graying (canities) inhibition, prevention, improvement, alleviation, delaying, or treatment effects.

Claims

1. A composition for suppressing hair graying, comprising at least one selected from the group consisting of escin, 27-deoxyactein, lysionotin, nitidine chloride, lanosterol, engeletin, specnuezhenide, praeruptorin B, rotunic acid, sesamoside, polygalacin D, momordin Ic, valechlorine, tussilagone, periplocin, polyphyllin VII and platycodin D2.

2. The composition for suppressing hair graying according to claim 1, which comprises at least one selected from the group consisting of escin, 27-deoxyactein, lysionotin, nitidine chloride, lanosterol, engeletin, specnuezhenide, praeruptorin B, rotunic acid, sesamoside, polygalacin D, momordin Ic, valechlorine, tussilagone, periplocin, polyphyllin VII and platycodin D2, in an amount of 0.0001-50 wt % based on the total weight of the composition.

3. The composition for suppressing hair graying according to claim 1, which activates the Wnt/β-catenin signaling system.

4. The composition for suppressing hair graying according to claim 1, which is a pharmaceutical composition, a quasi-drug composition or a cosmetic composition.

5. A hair care product or scalp care product for suppressing hair graying, comprising the composition for suppressing hair graying as defined in claim 1.

6. A kit for suppressing hair graying, comprising the composition for suppressing hair graying as defined in claim 1.

7. A method for suppressing hair graying, which comprises applying the composition for suppressing hair graying as defined in claim 1 to a subject in need thereof.

8. (canceled)

Description

DESCRIPTION OF DRAWINGS

[0028] FIG. 1 shows the test result illustrating an increase in melanin synthesis caused by escin in B-16 melanoma cells.

[0029] FIG. 2 is a graph illustrating an increase in melanin synthesis depending on escin and content thereof.

BEST MODE

[0030] Examples will be described more fully hereinafter so that the present disclosure can be understood with ease. The following examples may, however, be embodied in many different forms and should not be construed as limited to the exemplary embodiments set forth therein. Rather, these exemplary embodiments are provided so that the present disclosure will be thorough and complete, and will fully convey the scope of the present disclosure to those skilled in the art.

Test Example 1: Effect of Enhancing Wnt/β-Catenin Signaling

[0031] To determine activation of the Wnt/β-catenin signaling pathway, TCF/LEF Responsive Luciferase Reporter HEK293A stabilized cell line (Wnt Reporter HEK293A cell; WRHEK293A) was used in this test. The stabilized cell line was maintained through the subculture using MEM (Corning, USA) and fetal bovine serum (Gibco BRL, Gaithersburg, Md., USA). To carry out a transcriptional activity test, 30,000 cells were seeded per well in a 96-well plate and cultured in an incubator at 37° C. for 24 hours. Then, according to the present disclosure, treatment with each of escin, 27-deoxyactein, lysionotin, nitidine chloride, lanosterol, engeletin, specnuezhenide, praeruptorin B, rotunic acid, sesamoside, polygalacin D, momordin Ic, valechlorine, tussilagone, periplocin, polyphyllin VII and platycodin D2 was carried out as shown in the following Table 1. After culturing for 24 hours, a luciferase assay system (Promega) was used to perform reporter analysis. The analysis was carried out by the test method provided by the production company, and luminescence was determined by using Victor multiwall plate reader (PerkinElmer, USA). To determine cytotoxicity caused by the treatment, development of fluorescence of GFP as an internal control was determined. The luminescence value derived from the reaction with luciferase was divided by the GFP fluorescence value, and the values of the test group were calculated by taking the value of the non-treated control as 100% and expressed in the unit of percentage (%) (Table 1).

TABLE-US-00001 TABLE 1 Effect of Enhancing Wnt/β-Catenin Signaling Wnt signaling activation capability (%) Concentration (μg/mL) (Luminescence/GFP) Non-treated control 100 Escin 10 1098 27-Deoxyactein 10 1717 Lysionotin 10 196 Nitidine chloride 10 274 Lanosterol 10 194 Engeletin 10 223 Specnuezhenide 10 243 Praeruptorin B 10 241 Rotunic acid 10 296 Sesamoside 10 275 Polygalacin D 10 292 Momordin Ic 10 370 Valechlorine 10 218 Tussilagone 10 195 Periplocin 10 244 Polyphyllin VII 10 275 Platycodin D2 10 216

Test Example 2: Determination of Effect of Producing Melanin

[0032] In this test, the compounds in Test Example 1 showing an effect of enhancing the Wnt signaling were added to the culture medium of mouse-derived melanoma cells (B-16 mouse melanoma cells) to determine the effect of producing melanin in a cellular level (Lotan R., Lotan D. Cancer Res. 40: 3345-3350, 1980). Before the test, B-16 melanoma cells were evaluated in terms of toxicity, and the non-toxic concentration was selected to carry out evaluation of melanin production. B-16 melanoma cells were subcultured in DMEM (Gibco BRL., Gaithersburg, Md., USA) containing 10% FBS. Then, seeding to a 100 mm cell culture dish was performed to synthesize and extract melanin, and the cells were treated with each compound when the confluency was 70%. The compound was used for treating the cell culture at a concentration of 10 μg/mL. In addition, α-melanocyte stimulating hormone (α-MSH) was used as control, added to the culture medium to 10 nM to treat B-16 melanoma cells, and cultured for 48 hours. Then, the cells were treated with trypsin to strip them off the culture container, and centrifugal separation was carried out to extract melanin. After that, 1 mL of sodium hydroxide (1 N concentration) solution was added to the stripped cells and the mixture was boiled for 10 minutes so that melanin may be dissolved. The amount of melanin production was determined by measuring the absorbance at 400 nM by using a spectrophotometer. The amount of melanin was quantified in the unit of μg/mL by using a standard absorbance curve as a function of melanin concentration. The value of the non-treated control was taken as 100%, and the values of the test group were calculated as a percentage (%) on the basis thereof (Table 2).

TABLE-US-00002 TABLE 2 Melanin Synthesis Melanin synthesis Concentration (μg/mL) (%) Non-treated control 100 α-MSH (10 nM) 135 Escin 10 154 27-Deoxyactein 10 168 Lysionotin 10 135 Nitidine chloride 10 125 Lanosterol 10 110 Engeletin 10 121 Specnuezhenide 10 106 Praeruptorin B 10 136 Rotunic acid 10 144 Sesamoside 10 112 Polygalacin D 10 114 Momordin Ic 10 131 Valechlorine 10 139 Tussilagone 10 136 Periplocin 10 128 Polyphyllin VII 10 127 Platycodin D2 10 119

[0033] Among the compounds, the result of melanin synthesis derived from escin are shown in FIG. 1 and FIG. 2.

Test Example 3: Test for Determining Effect of Inhibiting Development of Gray Hair of Composition 1 (Hair Tonic) for Inhibiting Hair Graying

[0034] Composition 1 (hair tonic) including escin and 27-deoxyactein among the compounds according to the present disclosure for inhibiting hair graying was prepared. The composition was used to test the effect of reducing hair graying in the human hair. Herein, 60 healthy adults having gray hair participated in the test as subjects and were divided into five groups each including 12 subjects, and each test subject was allowed to use each of Comparative Example 1, Example 1, Example 1-2, Example 2 and Example 2-2 on his/her scalp for 6 months, 7 times per week. After the use, Folliscope phototrichogram was used to evaluate a degree of gray hair development as compared to the hair before applying the composition. The test result was expressed in the unit of percentage based on the value before application taken as 100%. The results are shown in Table 3.

TABLE-US-00003 TABLE 3 Degree of gray hair development Application After 4 After 8 After 12 After 24 Sample start weeks weeks weeks weeks Comp. Placebo control 100 ± 3% 105 ± 5% 109 ± 4% 119 ± 4% 125 ± 6% Ex. 1 Ex. 1 Escin 1% 100 ± 4% 104 ± 3% 105 ± 5% 107 ± 4% 107 ± 4% Ex. 1-2 Escin 1% 100 ± 4% 104 ± 2% 107 ± 4% 110 ± 4% 113 ± 5% free from ethanol Ex. 2 27-Deoxyactein 100 ± 3% 106 ± 2% 108 ± 2% 110 ± 7% 110 ± 6% 1% Ex. 2-2 27-Deoxyactein 100 ± 3% 105 ± 2% 108 ± 3% 113 ± 4% 115 ± 5% 1% free from ethanol

Preparation Example 1: Composition 1 for Inhibiting Hair Graying (Hair Tonic)

[0035] According to the present disclosure, each of escin, 27-deoxyactein, lysionotin, nitidine chloride, lanosterol, engeletin, specnuezhenide, praeruptorin B, rotunic acid, sesamoside, polygalacin D, momordin Ic, valechlorine, tussilagone, periplocin, polyphyllin VII and platycodin D2 was used to prepare hair tonic by using the conventional method according to the formulations as shown in the following Table 4.

TABLE-US-00004 TABLE 4 Fragrance Castor and Purified Ingredients Ethanol oil Glycerin Active ingredient pigment water Weight Comp. 55 5 3 0 q.s. Balance ratio Ex. 1 (total (%) Ex. 1 55 5 3 Escin 1 q.s. 100%) Ex. 1-2 0 5 3 Escin 1 q.s. Ex. 2 55 5 3 27-Deoxyactcin 1 q.s. Ex. 2-2 0 5 3 27-Deoxyactcin 1 q.s. Ex. 3 55 5 3 Lysionotin 1 q.s. Ex. 4 55 5 3 Nitidine chloride 1 q.s. Ex. 5 55 5 3 Lanosterol 1 q.s. Ex. 6 55 5 3 Engeletin 1 q.s. Ex. 7 55 5 3 Specnuezhenide 1 q.s. Ex. 8 55 5 3 Praeruptorin B 1 q.s. Ex. 9 55 5 3 Rotunic acid 1 q.s. Ex. 10 55 5 3 Sesamoside 1 q.s. Ex. 11 55 5 3 Polygalacin D 1 q.s. Ex. 12 55 5 3 Momordin Ic 1 q.s. Ex. 13 55 5 3 Valechlorine 1 q.s. Ex. 14 55 5 3 Tussilagone 1 q.s. Ex. 15 55 5 3 Periplocin 1 q.s. Ex. 16 55 5 3 Polyphyllin VII 1 q.s. Ex. 17 55 5 3 Platycodin D2 1 q.s.

Preparation Example 2: Composition 2 for Inhibiting Hair Graying (Hair Lotion)

[0036] According to the present disclosure, each of escin, 27-deoxyactein, lysionotin, nitidine chloride, lanosterol, engeletin, specnuezhenide, praeruptorin B, rotunic acid, sesamoside, polygalacin D, momordin Ic, valechlorine, tussilagone, periplocin, polyphyllin VII and platycodin D2 was used to prepare hair lotion by using the conventional method according to the formulations as shown in the following Table 5.

TABLE-US-00005 TABLE 5 Ingredients Weight ratio (%) Cetostearyl alcohol 2 Stearyltriethylammonium chloride 2 Hydroxyethyl cellulose 0.5 At least one of Escin, 27-Deoxyactein, 0.01 Lysionotin, Nitidine chloride, Lanosterol, Engeletin, Specnuezhenide, Praeruptorin B, Rotunic acid, Sesamoside, Polygalacin D, Momordin Ic, Valechlorine, Tussilagone, Periplocin, Polyphyllin VII and Platycodin D2 Fragrance and pigment q.s. Purified water Balance (total 100%)